We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

24 Feb 2024 - 28 Feb 2024
05 Mar 2024 - 07 Mar 2024

Blood Test Predicts Alzheimer's Risk 3.5 Years Before Clinical Diagnosis

By LabMedica International staff writers
Posted on 30 Jan 2023
Print article
Image: A blood-based test could predict onset of Alzheimer’s early in a non-invasive fashion (Photo courtesy of King’s College London)
Image: A blood-based test could predict onset of Alzheimer’s early in a non-invasive fashion (Photo courtesy of King’s College London)

A new study has found that a blood-based test can predict the risk of Alzheimer’s disease up to 3.5 years before clinical diagnosis. The study is based on the idea that components in the human blood are capable of modulating the formation of new brain cells, a process called neurogenesis which occurs in the hippocampus that plays a role in learning and memory. Alzheimer’s disease affects the formation of new brain cells in the hippocampus during its early stages, although previous research has managed to study neurogenesis only in its later stages by using autopsies.

Researchers at King’s College London (London, UK) set out to understand the early changes by collecting blood samples over a period of several years from 56 individuals with Mild Cognitive Impairment (MCI), a condition in which there is worsening of memory or cognitive ability. Not all individuals experiencing MCI can go on to develop Alzheimer’s disease, although those with the condition are diagnosed at a much higher rate compared to the wider population. Out of the 56 participants in the study, 36 went on to be diagnosed with Alzheimer’s disease.

In their study of how blood affected the brain cells, the researchers made a number of key discoveries. The participants from whom blood samples were collected over the years and who subsequently deteriorated and developed Alzheimer’s disease exhibited a decline in cell growth and division and a rise in apoptotic cell death (a process by which cells are programmed to die). However, the researchers found that these samples also upped the conversion of immature brain cells to hippocampal neurons.

The key reasons behind the increased neurogenesis are not yet known, although the researchers believe that it could be attributed to an early compensating mechanism for the neurodegeneration (loss of brain cells) experienced by individuals developing Alzheimer’s disease. Upon using only the blood samples collected furthest away from when the participants were diagnosed with Alzheimer’s disease, the researchers discovered that the changes in neurogenesis took place 3.5 years before a clinical diagnosis. These findings provide an opportunity to further understand the changes occurring in the brain at the earliest stages of Alzheimer’s disease, according to the researchers.

“Our findings are extremely important, potentially allowing us to predict onset of Alzheimer’s early in a non-invasive fashion,” said Dr. Edina Silajdžić, the study’s joint first author. “This could complement other blood-based biomarkers that reflect the classical signs of the disease, such as the accumulation of amyloid and tau (the ‘flagship’ proteins of Alzheimer’s disease).”

“It is now essential to validate these findings in a bigger and more diverse group of people,” added Dr. Hyunah Lee, the study’s joint first author. “We are excited about the potential applications of the blood-based test we used. For example, it can help stratify individuals with memory problems for a clinical trial of disease-modifying drugs for Alzheimer’s.”

Related Links:
King’s College London 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Wireless Point-of-Care Testing for Hepatitis B Virus (Photo courtesy of Chulalongkorn University)

Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step

Hepatitis B, a significant global health concern, is responsible for chronic liver diseases like cirrhosis and liver cancer which is one of the most common cancers worldwide. The challenge with hepatitis... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Pathology

view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more

Industry

view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.